An official website of the United States government

Publication Information

PubMed ID
Public Release Type
Journal
Publication Year
2018
Affiliation
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN; European University of Western Brittany, CHU Brest, Brest, France.; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.; Department of Clinical Genomics, Mayo Clinic, Rochester, MN.; Division of Child and Adolescent Neurology, Mayo Clinic, Rochester, MN.; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.; The Kidney Institute, Department of Internal Medicine, Kansas University Medical Center, Kansas City, KS.; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. Electronic address: harris.peter@mayo.edu.
Authors
Cornec-Le Gall Emilie, Chebib Fouad T, Madsen Charles D, Senum Sarah R, Heyer Christina M, Lanpher Brendan C, Patterson Marc C, Albright Robert C, Yu Alan S, Torres Vicente E, Harris Peter C
Studies

Abstract

The diagnosis of autosomal dominant polycystic kidney disease (ADPKD) relies on imaging criteria in the setting of a positive familial history. Molecular analysis, seldom used in clinical practice, identifies a causative mutation in >90% of cases in the genes PKD1, PKD2, or rarely GANAB. We report the clinical and genetic dissection of a 7-generation pedigree, resulting in the diagnosis of 2 different cystic disorders. Using targeted next-generation sequencing of 65 candidate genes in a patient with an ADPKD-like phenotype who lacked the familial PKD2 mutation, we identified a COL4A1 mutation (p.Gln247*) and made the diagnosis of HANAC (hereditary angiopathy with nephropathy, aneurysms, and muscle cramps) syndrome. While 4 individuals had ADPKD-PKD2, various COL4A1-related phenotypes were identified in 5 patients, and 3 individuals with likely digenic PKD2/COL4A1 disease reached end-stage renal disease at around 50 years of age, significantly earlier than observed for either monogenic disorder. Thus, using targeted next-generation sequencing as part of the diagnostic approach in patients with cystic diseases provides differential diagnoses and identifies factors underlying disease variability. As specific therapies are rapidly developing for ADPKD, a precise etiologic diagnosis should be paramount for inclusion in therapeutic trials and optimal patient management.